Investor Relations

Latest Financial Results

Q2 2026

Quarter Ended Jun 30, 2026

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2025

Company Overview

BullFrog AI harnesses artificial intelligence and machine learning to advance pharmaceutical R&D and drug target discovery, providing AI-accelerated outputs that are optimized and human-validated.

BullFrog AI operates through three complementary capabilities, deployable independently or as a combined platform: bfPREP™ for biology-aware data harmonization, bfLEAP® for causal AI analytics and patient subgroup discovery, and bfARENAS™ for structured, auditable decision support. The common thread across all three: every output is traceable, every analytical decision is logged, and every recommendation is designed to be reviewed and validated by the scientific team before it drives a decision.

Our mission is to improve lives by identifying critical connections between therapies and highly responsive patients – in less time, with less cost, and more precision.

Stock Snapshot

IR Contacts

Headquarters

BullFrog AI Holdings, Inc.
325 Ellington Blvd.
#317
Gaithersburg, MD 20878
T: 240-658-6710
info@bullfrogai.com

Investor Relations

Core IR
Rory Rumore
Senior Vice President, Investor Relations
377 Oak St
Garden City, NY 11530
USA
M: 1 (212) 655-0924
ir@bullfrogai.com
https://coreir.com

Transfer Agent

VStock Transfer, LLC
18 Lafayette Place
Woodmere, NY 11598
T: 212-828-8436
F: 646-536-3179
0-K@vstocktransfer.com